Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA Biologics: Why The Dip To $16 Resets The Buy Case
ADMA Biologics remains a Buy as Q3 results and 2026 guidance support a bullish long-term outlook. ADMA's Asceniv drives robust revenue and margin expansion, with 2026 revenue guided at $630M and EBITDA margin at 56%. Yield-enhanced manufacturing and facility expansion position ADMA for further growth, while SG-001 offers optionality beyond 2029.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Adma Biologics (ADMA) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Adma Biologics (ADMA) is looking like an interesting pick, as it just reached a key level of support. ADMA recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Adma Biologics (ADMA) Crossed Above the 50-Day Moving Average: What That Means for Investors
Adma Biologics (ADMA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ADMA broke through the 50-day moving average, which suggests a short-term bullish trend.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
ADMA Biologics, Inc. (ADMA) Q3 2025 Earnings Call Transcript
ADMA Biologics, Inc. ( ADMA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Adam Grossman - Co-Founder, President, CEO & Director Brad Tade - CFO & Treasurer Conference Call Participants Anthony Petrone - Mizuho Securities USA LLC, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Presentation Operator Good afternoon, and welcome to the ADMA Biologics Third Quarter 2025 Financial Results and Business Update Conference Call on Wednesday, November 5 2025. [Operator Instructions] Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call.
Adma Biologics (ADMA) Q3 Earnings Match Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.16 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.15 per share a year ago.
ADMA Biologics Inc (ADMA) Is a Trending Stock: Facts to Know Before Betting on It
Adma Biologics (ADMA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
Adma Biologics (ADMA) closed at $14.56 in the latest trading session, marking a -3.51% move from the prior day.
Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Why Adma Biologics (ADMA) Outpaced the Stock Market Today
Adma Biologics (ADMA) concluded the recent trading session at $15.05, signifying a +2.66% move from its prior day's close.
